Clinical Improvement

Selected news for the healthcare topic - Clinical Improvement, collected since 10/2017. Recent stories appear in harvard.edu. This healthcare topic shares news with COVID-19, Gilead, Infectious Disease, Food and Drug Administration, Gilead Sciences and over a hundred others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
5/21/2021 Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review harvard.edu ... of 34 specific compounds and 4 groups of drugs identified in a previous scoping review. Studies will be identified both from traditional literature databases and pre-print servers. Outcomes assessed will include time to clinical improvement , time to viral clearance, mortality, length of hospital stay, and proportions transferred to the intensive care unit and intubated, respectively. We will use the GRADE methodology to assess the quality of the evidence. DISCUSSION ...
5/21/2021 Repurposing Existing Medications for Coronavirus Disease 2019: Protocol for a Rapid and Living Systematic Review harvard.edu ... of 34 specific compounds and four groups of drugs identified in a previous scoping review. Studies will be identified both from traditional literature databases and pre-print servers. Outcomes assessed will include time to clinical improvement , time to viral clearance, mortality, length of hospital stay, and proportions transferred to the intensive care unit and intubated, respectively. We will use the GRADE methodology to assess the quality of the evidence. DISCUSSION ...
5/20/2021 Inhaled Treprostinil Improves Clinical Status in Pulmonary Hypertension-ILD pulmonologyadvisor.com ... 16-week INCREASE study (ClinicalTrials.gov Identifier: NCT02630316 ), which assessed the efficacy and safety of inhaled treprostinil vs placebo in patients with PH-ILD. In a post hoc analysis, researchers evaluated a composite endpoint comprising clinical improvement at week 16 in 326 patients. The composite of clinical improvement included the absence of clinical worsening, ‚â•10% improvement in 6-minute walk distance (6MWD) or ‚â•10% improvement in forced vital capacity ...
5/19/2021 BerGenBio fails COVID-19 trial, makes post hoc case for program FierceBiotech ... were on oxygen at baseline. (BerGenBio)A phase 2 clinical trial of BerGenBio’s bemcentinib in hospitalized COVID-19 patients has missed its primary endpoint. The AXL inhibitor failed to accelerate time to sustained clinical improvement over standard of care, but BerGenBio identified a subgroup analysis of a secondary endpoint as a reason to continue development.BerGenBio set out to show that adding bemcentinib to standard of care reduces the ...
5/18/2021 Bergenbio undeterred by bemcentinib miss in COVID-19 trial as subgroup analysis identifies a forward path 18 BioWorld ... Its repurposed AXL kinase inhibitor, bemcentinib , plus standard of care was marginally better than standard of care alone in an open-label phase II trial in hospitalized COVID-19 patients in reducing time to clinical improvement (an improvement of two points or more on the WHO’s nine-point disease severity scale) or time to discharge or fitness for discharge, but the difference was not statistically significant.Nevertheless, the Bergen ...
5/17/2021 Clinical Trial Suggests Convalescent Plasma May Improve Survival with Severe COVID-19 columbia.edu ... de Janeiro, Brazil; University of Washington; and New York Blood Center. The results are published in the Journal of Clinical Investigation .According to the investigators, one possible explanation for the discrepancy between lack of clinical improvement and improved survival is that severely ill Covid-19 patients survived but remained hospitalized at their baseline status. The study also reports trends towards improved clinical status among patients who received convalescent plasma less ...
5/3/2021 Synairgen's inhaled treatment lowers Covid-19 hospitalisation rate clinicaltrialsarena.com ... caused by SARS-CoV-2. It enrolled 221 subjects across two cohorts – hospital and home.The primary endpoint of the trial was the change in condition assessed using the WHO Ordinal Scale for Clinical Improvement (OSCI) during dosing.The hospital cohort had 101 subjects in the hospital setting. Data showed that patients receiving SNG001 versus placebo were more likely to recover from severe LRT illness to an extent where ...
4/30/2021 5 fundamental beliefs that block digital transformation in health systems bollyinside.com ... over 100 of the country’s largest health systems and conversations with dozens more, we have uncovered five core beliefs that currently prevent many health systems from rapidly innovating and achieving significant operational and clinical improvement . Here are the five core beliefs and why they need to be overcome for a successful transformation:1. “Our EHR can do it all.” 3. “Anything we need beyond the EHR we can ...
4/22/2021 Investigator-sponsored trial being conducted at ma wapakdailynews.com ... is expected to enroll 80 patients, who will receive either RLF-100 together with standard of care or placebo plus standard of care. The primary endpoint is the time (in days) from hospitalization to clinical improvement , up to day 28. Clinical improvement shall be defined as either alive hospital discharge or a decrease of two or more points on the WHO-recommended nine-point ordinal scale of clinical status (WHO ...
4/22/2021 The Ridgway Record ridgwayrecord.com ... is expected to enroll 80 patients, who will receive either RLF-100 together with standard of care or placebo plus standard of care. The primary endpoint is the time (in days) from hospitalization to clinical improvement , up to day 28. Clinical improvement shall be defined as either alive hospital discharge or a decrease of two or more points on the WHO-recommended nine-point ordinal scale of clinical status (WHO ...
4/22/2021 Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress Syndrome otcmarkets.com ... is expected to enroll 80 patients, who will receive either RLF-100 together with standard of care or placebo plus standard of care. The primary endpoint is the time (in days) from hospitalization to clinical improvement , up to day 28. Clinical improvement shall be defined as either alive hospital discharge or a decrease of two or more points on the WHO-recommended nine-point ordinal scale of clinical status (WHO ...
4/22/2021 Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress Syndrome otcmarkets.com ... is expected to enroll 80 patients, who will receive either RLF-100 together with standard of care or placebo plus standard of care. The primary endpoint is the time (in days) from hospitalization to clinical improvement , up to day 28. Clinical improvement shall be defined as either alive hospital discharge or a decrease of two or more points on the WHO-recommended nine-point ordinal scale of clinical status (WHO ...
4/21/2021 Riociguat May Be Useful Alternative to PDE5i Therapy in Pulmonary Arterial Hypertension pulmonologyadvisor.com ... option for patients with pulmonary arterial hypertension (PAH) in whom phosphodiesterase-5 inhibitor (PDE5i) treatment is insufficient, according to the results of a recent study published in the journal Lancet Respiratory Medicine .Researchers evaluated clinical improvement , defined as an absence of clinical worsening and prespecified improvements in at least 2 of 3 variables, in patients with symptomatic PAH at intermediate risk for 1-year mortality in the REPLACE open-label ...
4/20/2021 Todos Medical – Tollovir™ (NLC-V-01) genengnews.com ... will evaluate the safety and efficacy of Tollovir for the treatment of COVID-19 in hospitalized patients. The trial’s primary endpoints are time to discharge from the hospital, and time to clinical improvement based upon the National Early Warning Score 2 (NEWS2) in Israel.On April 1, a team of U.S. researchers published a preclinical study in Nature Communications identifying three structurally diverse compounds—compound 4 ...
4/19/2021 Todos Medical Launches Phase 2 Clinical Trial of Its Antiviral 3CL Protease Inhibitor NLC-V-01 (Tollovir) in Hospitalized COVID-19 Patients drugs.com ... candidates for development of antiviral therapies against SARS-CoV-2 (the virus that causes COVID-19).The primary endpoints of the Clinical Trial being examined are: Time to discharge from the hospital Time to clinical improvement based upon the National Early Warning Score 2 (NEWS2) in IsraelThe secondary endpoints of Clinical Trial being examined are: Rate of change of measured parameters Rate of change in vital signs (blood pressure ...
4/13/2021 Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial in Non-Mechanically Ventilated Severe COVID-19 Patients drugs.com ... 0.1224 met predefined statistical threshold of p 0.2) 65% reduction in risk of mechanical ventilation/death with mavrilimumab versus placebo (p=0.0175) 61% reduction in risk of death with mavrilimumab versus placebo (p=0.0726) Clinical improvement was observed on top of steroids and/or antivirals Enrollment in the Phase 3 portion of the trial ongoingHAMILTON, Bermuda, April 12, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a ...